Z. Cabantchik

发表

Mode of action of iron (III) chelators as antimalarials: II. Evidence for differential effects on parasite iron-dependent nucleic acid synthesis.

S. Lytton, B. Mester, J. Libman, 1994, Blood.

of ferroportin up-regulation iron absorption mediated by down-regulation of hepcidin and -thalassemia is characterized by increased β Ineffective erythropoiesis in

Z. Cabantchik, N. Amariglio, G. Rechavi, 2013 .

On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure

Z. Cabantchik, M. Roughton, D. Pennell, 2011, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

Iron chelators: mode of action as antimalarials.

J. Golenser, Z. Cabantchik, I. Cabantchik, 1996, Acta haematologica.

Chelation and mobilization of cellular iron by different classes of chelators.

P. Milgram, J. Libman, A. Shanzer, 1997, Molecular pharmacology.

LPI-labile plasma iron in iron overload.

Z. Cabantchik, P. Cianciulli, W. Breuer, 2005, Best practice & research. Clinical haematology.

The biochemical basis for the selective antimalarial action of iron chelators on Plasmodium falciparum parasitized cells.

S. Lytton, B. Mester, J. Libman, 1994, Advances in experimental medicine and biology.

Mode of action of iron (III) chelators as antimalarials: II. Evidence for differential effects on parasite iron-dependent nucleic acid synthesis

S. Lytton, B. Mester, J. Libman, 1994 .

Non‐transferrin bound iron in Thalassemia: Differential detection of redox active forms in children and older patients

Z. Cabantchik, W. Breuer, E. Rachmilewitz, 2012, American journal of hematology.

Objectives and Mechanism of Iron Chelation Therapy

Z. Cabantchik, G. Link, Z. Cabantchik, 2005, Annals of the New York Academy of Sciences.

Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells.

A. Shanzer, Z. Cabantchik, W. Breuer, 1996, Blood.

versus mammalian cells Differential cytotoxicity of iron chelators on malaria-infected cells

A. Shanzer, Z. Cabantchik, W. Breuer, 2011 .

The treatment of animal models of malaria with iron chelators by use of a novel polymeric device for slow drug release.

J. Golenser, Z. Cabantchik, W. Eling, 1997, The Journal of pharmacology and experimental therapeutics.

Mode of action of iron(III) chelators as antimalarials. III. Overadditive effects in the combined action of hydroxamate-based agents on in vitro growth of Plasmodium falciparum.

J. Golenser, J. Libman, A. Shanzer, 1995, Molecular Pharmacology.

Chemical Determinants of antimalarial activity of reversed siderophores

J. Libman, A. Shanzer, Z. Cabantchik, 1996, Antimicrobial agents and chemotherapy.

Mode of action of iron (III) chelators as antimalarials. IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives.

Z. Cabantchik, P. Ponka, M. Loyevsky, 1996, The Journal of laboratory and clinical medicine.

Role of Iron in Inducing Oxidative Stress in Thalassemia: Can It Be Prevented by Inhibition of Absorption and by Antioxidants?

S. Rivella, Z. Cabantchik, K. Adamsky, 2005, Annals of the New York Academy of Sciences.

Iron chelators as anti-infectives; malaria as a paradigm.

Z. Cabantchik, V. Gordeuk, S. Moody-Haupt, 1999, FEMS immunology and medical microbiology.

Antimalarial action of hydroxamate-based iron chelators and potentiation of desferrioxamine action by reversed siderophores

J. Golenser, J. Libman, A. Shanzer, 1995, Antimicrobial agents and chemotherapy.

In vivo antimalarial action of a lipophilic iron (III) chelator: Suppression of plasmodium vinckei infection by reversed siderophore

B. Mester, J. Libman, A. Shanzer, 1993, American journal of hematology.

The antimalarial action of desferal involves a direct access route to erythrocytic (Plasmodium falciparum) parasites.

S. Lytton, B. Mester, J. Libman, 1993, The Journal of clinical investigation.

Mode of action of iron (III) chelators as antimalarials: I. Membrane permeation properties and cytotoxic activity.

S. Lytton, B. Mester, J. Libman, 1993, Blood.

Reversed siderophores as antimalarial agents. II. Selective scavenging of Fe(III) from parasitized erythrocytes by a fluorescent derivative of desferal.

S. Lytton, J. Libman, A. Shanzer, 1991, Molecular pharmacology.

Reversed siderophores act as antimalarial agents.

S. Lytton, J. Libman, A. Shanzer, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Monitoring of iron(III) removal from biological sources using a fluorescent siderophore.

S. Lytton, B. Mester, J. Libman, 1992, Analytical biochemistry.

differential effects on parasite iron-dependent nucleic acid synthesis Mode of action of iron (III) chelators as antimalarials: II. Evidence for

S. Lytton, B. Mester, J. Libman, 2011 .

Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.

Yi Fang Liu, S. Rivella, N. Andrews, 2006, Blood.

Covalent modification of the permeability pathways induced in the human erythrocyte membrane by the malarial parasite Plasmodium falciparum

H. Ginsburg, Z. Cabantchik, W. Breuer, 1987, Journal of cellular physiology.

Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.

Z. Cabantchik, P. Pootrakul, W. Breuer, 2001, Blood.

Antimalarial action of hydrophilic drugs: involvement of aqueous access routes to intracellular parasites.

Z. Cabantchik, M. Loyevsky, 1994, Molecular pharmacology.

Transferrin therapy ameliorates disease in β-thalassemic mice

Charles B. Hall, Z. Cabantchik, E. Bouhassira, 2010, Nature Medicine.

Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation.

A. Munnich, Z. Cabantchik, O. Kakhlon, 2010, Canadian journal of physiology and pharmacology.

Exogenous iron increases hemoglobin in beta-thalassemic mice.

Charles B. Hall, R. Nagel, Z. Cabantchik, 2009, Experimental hematology.

Labile plasma iron in iron overload: redox activity and susceptibility to chelation.

Z. Cabantchik, P. Pootrakul, W. Breuer, 2003, Blood.

Iron Overload and Apoptosis of HL-1 Cardiomyocytes: Effects of Calcium Channel Blockade

Z. Cabantchik, Y. Cheung, G. C. Chan, 2014, PloS one.

Targeting Chelatable Iron as a Therapeutic Modality in Parkinson ’ s Disease

L. Defebvre, K. Dujardin, A. Destée, 2016 .

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

Z. Cabantchik, P. Greenberg, G. Warsi, 2010, Leukemia research.

Iron Acquired from Transferrin by K562 Cells Is Delivered into a Cytoplasmic Pool of Chelatable Iron(II) (*)

Z. Cabantchik, W. Breuer, Z. Cabantchik, 1995, The Journal of Biological Chemistry.

Redox active plasma iron in C282Y/C282Y hemochromatosis.

M. Pouchard, Z. Cabantchik, P. Brissot, 2005, Blood.

Neurological Disorders Associated with Iron Misdistribution: The Therapeutic Potential of Siderophores

A. Munnich, Z. Cabantchik, O. Kakhlon, 2011 .

The cellular labile iron pool and intracellular ferritin in K562 cells.

Z. Cabantchik, I. Slotki, E. Meyron-Holtz, 1999, Blood.

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

Z. Cabantchik, P. Greenberg, G. Warsi, 2010, Leukemia research.

The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation.

Z. Cabantchik, I. Slotki, W. Breuer, 2000, Blood.

Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.

Z. Cabantchik, G. Link, P. Ponka, 2003, Blood.